The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENLV | +12.62% | -93.89% | -42.8% | -89% |
| S&P | +13.95% | +78.35% | +12.25% | +146% |
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
No news articles found for Enlivex Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$81.00K | 49.7% |
| Market Cap | $24.81M | -31.0% |
| Market Cap / Employee | $689.24K | 0.0% |
| Employees | 36 | 0.0% |
| Net Income | -$2,205.00K | 15.3% |
| EBITDA | -$2,476.00K | 16.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.20M | 45.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $426.00K | 1.7% |
| Short Term Debt | $275.00K | -20.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -50.07% | -0.7% |
| Return On Invested Capital | -51.41% | 3.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,319.03K | 12.3% |
| Operating Free Cash Flow | -$2,295.48K | 12.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.97 | 0.97 | 1.29 | 1.30 | 6.02% |
| Price to Tangible Book Value | 0.97 | 0.80 | 1.29 | 1.30 | 6.02% |
| Enterprise Value to EBITDA | -0.84 | -0.85 | -2.53 | -2.99 | -25.75% |
| Return on Equity | -55.9% | -60.3% | -55.0% | -57.6% | -0.49% |
| Total Debt | $534.00K | $503.00K | $480.00K | $701.00K | -8.37% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
